Orchid Pharma's Q1 FY25 financials show mixed results, with potential for future growth

Orchid Pharma, a midcap pharmaceutical company, recently declared its financial results for the quarter ending June 2024. According to the report, the company’s performance has remained flat compared to the previous quarter, with a score of -1 as opposed to 14 in the last 3 months.

Despite this, there are some positive aspects to the company’s financials. The Profit After Tax (PAT) for the nine-month period has shown a growth of 20.65% year on year, with a current value of Rs 82.19 crore. This indicates a positive trend in the near term for the company. Additionally, the PAT for the nine-month period is higher than the preceding 12-month period, which shows a steady increase in sales.

However, there are also some areas of concern for Orchid Pharma. The Profit Before Tax less Other Income (PBT) for the quarter has fallen by -40.3% compared to the average PBT of the previous four quarters. This indicates a very negative trend in the near term. Furthermore, the company’s non-operating income, which is 43.98% of the PBT, is at its highest in the last five quarters. This suggests that the company’s income from non-business activities is high, which may not be a sustainable business model.

In conclusion, while Orchid Pharma’s financial results for the quarter ending June 2024 may not be as positive as expected, there are still some promising aspects to the company’s performance. Investors are advised to hold their stocks, as recommended by MarketsMOJO, and keep an eye on the company’s future financial reports.